Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice

Claudia Palladino, María Luisa Navarro Gómez, Pere Soler-Palacín, María Isabel González-Tomé, Santiago J. De Ory, María Espiau, Santiago Pérez Hoyos, Juan Antonio León-Leal, María Méndez, David Moreno-Pérez, Claudia Fortuny Guasch, Antoni Mur Sierra, Itziar Pocheville Guruceta, Santiago Moreno Guillén, Verónica Briz

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

4 Cites (Scopus)

Resum

© Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
Idioma originalAnglès
Pàgines (de-a)2155-2159
RevistaAIDS
Volum29
Número16
DOIs
Estat de la publicacióPublicada - 23 d’oct. 2015

Fingerprint

Navegar pels temes de recerca de 'Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice'. Junts formen un fingerprint únic.

Com citar-ho